Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,893 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05789069 | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 83 | HiFiBiO TherapeuticsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT06882915 | Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study | not yet recruiting | Phase 1 | 20 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT06307548 | Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01719926 | Phase I Platinum Based Chemotherapy Plus Indomethacin(PIFA) | completed | Phase 1 | 13 | UMC UtrechtOTHER | 2 | Jun 4, 2026 | clinicaltrials |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | recruiting | Phase 1 | 604 | Revolution Medicines, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624214 | Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors | not yet recruiting | Phase 1 | 198 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT00159484 | Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 75 | University of Southern CaliforniaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT02403505 | Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer(CEA+RC-BCG) | active not recruiting | Phase 1 | 20 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT00600496 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | completed | Phase 1 | 140 | AstraZenecaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03095781 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 47 | Emory UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07587619 | Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion | active not recruiting | Phase 1 / Phase 2 | 52 | University of Southern CaliforniaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT03386500 | Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT07014878 | A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 18 | Beijing DCTY Biotech Co.,Ltd.OTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07591597 | A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer(IGNITE-CRC) | not yet recruiting | Phase 1 / Phase 2 | 68 | National Cancer Center Hospital EastOTHER | 0 | May 18, 2026 | clinicaltrials |
| NCT05334004 | Lopinavir/Ritonavir in PLWH With High-Grade AIN | recruiting | Phase 1 | 21 | University of Wisconsin, MadisonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer(DUO-CRC-NK-111) | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07587827 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer(ODI-2001-01) | not yet recruiting | Phase 1 | 77 | Centre Georges Francois LeclercOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07365592 | Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC(Neo-CD) | recruiting | Phase 1 / Phase 2 | 138 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03017807 | Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | recruiting | Phase 1 | 22 | University of California, IrvineOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | suspended | Phase 1 / Phase 2 | 53 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07417488 | GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas | recruiting | Phase 1 | 18 | Thomas Jefferson UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT05692024 | COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER(COMMENCER) | recruiting | Phase 1 / Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | terminated | Phase 1 | 68 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT07566897 | A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 96 | Philogen S.p.A.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02837263 | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | completed | Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07283367 | A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. | recruiting | Phase 1 / Phase 2 | 502 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07561060 | Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy(TNTIT) | recruiting | Phase 1 / Phase 2 | 50 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 124 | MacroGenicsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2026source: clinicaltrials